PrecisionLife CEO Dr Steve Gardner joins the CNS Summit community to present an Innovation Showcase on mechanism-based patient stratification followed by an expert precision neuroscience session, both designed to help biopharma inform and derisk their R&D in complex chronic diseases.
INNOVATION SHOWCASE
Friday 10 November at 11:30am (EST)
In this session Steve will explain how novel mechanism-based patient stratification biomarkers are being used to inform and derisk every stage of drug discovery and clinical development.
NEUROSCIENCE SESSION
Friday 10 November at 1:30pm (EST)
A special precision neuroscience session introducing a new era of precision medicine in neurological, psychiatric, and neurodegenerative diseases with case stories from multiple CNS strategic R&D collaborations with our pharma partners.
Apply now to join CNS Summit, login to the event platform to connect with Steve or contact us to request a meeting.
PrecisionLife focuses on precision medicine analytics in complex chronic diseases, including CNS, autoimmune, cardiovascular, respiratory and metabolic diseases. We have multiple strategic R&D collaborations with biopharma companies, and have generated deep disease insights in 50 diseases.
We map novel targets to specific patient subgroups with causal genetic and mechanistic explanations and disease prelevance. Our patient stratification biomarkers help design smaller, faster, more targeted clinical trials and to build highly predictive complementary diagnostics. We also work with biopharma companies to reevaluate clinical trial results, identify secondary indications and out-licensing opportunities for pipeline and/or stalled assets.
Contact us to learn more about PrecisionLife